Navigation Links
Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
Date:11/6/2008

rward- looking statements as a result of several factors, including regulatory approval requirements and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the company's reports on Forms 10-K, 10-Q, and other filings with the Securities and Exchange Commission.

HALOZYME THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - UNAUDITED

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2008 AND 2007

Three Months Ended Nine Months Ended

September 30, September 30,

2008 2007 2008 2007

REVENUES:

Revenue under

collaborative

agreements $2,194,325 $757,629 $5,209,897 $1,920,192

Product sales 267,901 185,252 492,066 541,420

Total Revenues 2,462,226 942,881 5,701,963 2,461,612

OPERATING EXPENSES:

Cost of product

sales 130,720 59,454 205,036 211,200

Research and

development 10,080,775 6,352,397 27,450,454 13,265,645

Selling, general

and administrative 3,450,450 2,840,683 11,454,228 7,207,544

Total Operating

Expenses 13,661,945 9,252,534 39,109,718 20,684,389

LOSS FROM OPERATIONS (11,199,719) (8,309,653) (33,407,755) (18,222,777)

Interest income 327,561 1,280,871 1,579,210 3,034,985

NET LOSS $(10,872,158) $(7,028,782) $(31,828,545) $(15,187,792)

Basic and diluted

net loss per share $(0.14) $(0.09) $(0.40) $(0.21)

Shares used in

computing net loss

per share,

basic and diluted 80,293,800 76,502,867 79,383,614 73,259,130

<
'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
2. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
3. Halozyme Therapeutics to Present at Upcoming Investor Conferences
4. Halozyme Therapeutics to Host Research Day for Investors and Analysts
5. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
6. Halozyme Therapeutics to Present at Upcoming Investor Conferences
7. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
8. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
9. Halozyme Therapeutics to Present at the Jefferies 2nd Annual Healthcare Conference
10. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
11. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Feb. 27, 2015  Steep Hill, the industry leader ... internationally, intends to open a full service medical cannabis ... , bringing advanced scientific tools and methodology to ... Steep Hill is currently the only laboratory licensed by ... and contaminant testing in order to meet the recently ...
(Date:2/26/2015)... N.J. , Feb. 26, 2015 On ... and its affiliated companies, Wilentz, Goldman & Spitzer, ... trade secrets lawsuit against Genewiz Inc. in excess of ... and utilized GenScript,s trade secrets, and that it improperly ... entered an order denying motions for judgment notwithstanding the ...
(Date:2/26/2015)... LEXINGTON, Mass., Feb. 26, 2015   Synageva ... a biopharmaceutical company developing therapeutic products for rare ... and provided 2015 goals, other key objectives, and ... conference call today at 4:30 p.m. EST to ... business update.  To participate in today,s call by ...
(Date:2/26/2015)... , Feb. 26, 2015 DuPont Executive Vice ... driven by key research advancements and product launches across ... Bank of America Merrill Lynch 2015 Global Agriculture Conference. ... of building grain supplies the last two years, long-term ... the pace of the last decade, when demand for ...
Breaking Biology Technology:Steep Hill First to Receive Provisional Approval to Establish Laboratory Services for Cannabis Testing in State of New Mexico 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 2DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 3DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 4DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 5
... Icahn confirmed today that,entities affiliated with him have given ... persons at Biogen,s forthcoming 2008 Annual,Meeting of Stockholders to ... board of twelve directors, and there are four directorships,up ... "We are taking this action because we believe,that Biogen,s ...
... The VenaFlux(TM) Platform Accurately Mimics a Human ... Cellix Ltd., an international,provider of microfluidic systems ... its worldwide launch of its VenaFlux(TM),Platform. The ... based assay system, measures cell adhesion to,antibody-coated ...
... Alexion,Pharmaceuticals, Inc. (Nasdaq: ALXN ), today announced that ... cast on Thursday, February 14,2008, at 10:00 a.m. Eastern ... results for the fourth quarter and full year ended ... 6:30 a.m.,ET on Thursday, February 14, 2008., To ...
Cached Biology Technology:Icahn Confirms Intention to Nominate Three Directors at Biogen 2Icahn Confirms Intention to Nominate Three Directors at Biogen 3Cellix Ltd. Launches the First Semi-Automated, High Throughput Cell-Adhesion Assay Platform 2
(Date:2/23/2015)... 23, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... 62114357 for DISTRIBUTED VOICE DIRECTED PAYMENT METHOD ... a new groundbreaking payment method. Payment accounts may be ... only be accessed if both the speech (the word ...
(Date:2/12/2015)... OXFORD, Conn. , Feb. 12, 2015 ... ("NXT-ID" or the "Company"), a biometric authentication company focused ... it has filed provisional patent 62/113114 for ... MULTIPLE DEVICES. The patent further establishes NXT-ID,s ... to its intellectual property portfolio the ability for multiple ...
(Date:2/5/2015)... 5, 2015  Marken is starting its 35 th ... launched a new marketing campaign to solidify its place ... new campaign focuses on First as a ... The first headline in the series, ... with its client,s priorities. Marken recognizes the need to ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Marken Launches New Patient-Centric Campaign 2
... Columbine flowers are recognizable by the long, trailing nectar ... tempting the taste buds of their insect pollinators. ... Santa Barbara (UCSB) helps to explain how columbines have ... flowers apparently tailored to the length of their pollinators, ...
... partnership with the Office of Naval Research (ONR), Marines ... disposal system that can reduce a standard 50-gallon bag ... Called the Micro Auto Gasification System (MAGS), the ... Forces, Pacific (MARFORPAC) as a possible solution to help ...
... today demonstrates the brain,s remarkable capacity to repair itself. ... limit damage after blood and oxygen deprivation and blood ... Neuroscience,s annual meeting and the world,s largest source of ... is the number one cause of long-term disability and ...
Cached Biology News:Dramatic diversity of columbine flowers explained by a simple change in cell shape 2Dramatic diversity of columbine flowers explained by a simple change in cell shape 3Marines test new energy-efficient weapon in the war on trash 2Brain, repair thyself: Studies highlight brain's resiliency to damage 2
Human SCP3 Affinity Purified Polyclonal Ab Keywords: Spermatogenesis, meiosis Protein Family: Cell Cycle...
... NAP-10 Columns, 50. For rapid and ... 10-mers) in less than 15 minutes by ... in distilled water containing 0.15% Kathon CG/ICP ... volume: 0.5 ml (NAP-5), 1 ml ...
Homo sapiens alcohol dehydrogenase 5 (class III), chi polypeptide (ADH5), mRNA....
Human Serpin A3 MAb (Clone 213907)...
Biology Products: